CLL malignant B cells express significantly higher CCND2 than CCND1 levels (Supplementary Fig. 7b) and as in CCND2high myeloma PC, we found that the same CCND2 super-enhancer is active in CLL B cells (Supplementary Fig. 7a). This evidence concerns the gene CCND2 and plasma cell myeloma.